Zobrazeno 1 - 10
of 83
pro vyhledávání: '"Yu-Yan Hwang"'
Autor:
Lok-Ka Lam, Thomas Sau Yan Chan, Yu-Yan Hwang, Lung-Yi Mak, Wai-Kay Seto, Yok-Lam Kwong, Man-Fung Yuen
Publikováno v:
Virology Journal, Vol 20, Iss 1, Pp 1-4 (2023)
Abstract Background Ibrutinib is a Bruton’s tyrosine kinase (BTK) inhibitor approved for the treatment for several mature B-cell malignancies. Reactivation of hepatitis B virus (HBV) is a well-described complication in patients with chronic HBV inf
Externí odkaz:
https://doaj.org/article/cc05b311d10c40598f58c56123be4618
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 684-690 (2022)
Background Epstein Barr virus positive (EBV+) immunodeficiency-associated lymphoproliferative disorders (IA-LPD) are heterogeneous diseases with variable treatment strategies that are not well-defined.Case presentation A 68-year-old woman with system
Externí odkaz:
https://doaj.org/article/cf7cac74a1654390ae310c0ba9883ad8
Publikováno v:
Hematology, Vol 27, Iss 1, Pp 535-542 (2022)
Objectives Bendamustine is a standard treatment for low-grade B-cell lymphomas, and considered safe in clinical trials. Its safety in routine practice might be different.Methods We retrospectively analyzed the infection complications in an unselected
Externí odkaz:
https://doaj.org/article/e9e8908c358148bda5dc1d15fe8d661e
Autor:
Harinder Gill, Rita Yim, Herbert H. Pang, Paul Lee, Thomas S. Y. Chan, Yu‐Yan Hwang, Garret M. K. Leung, Ho‐Wan Ip, Rock Y. Y. Leung, Sze‐Fai Yip, Bonnie Kho, Harold K. K. Lee, Vivien Mak, Chi‐Chung Chan, June S. M. Lau, Chi‐Kuen Lau, Shek‐Yin Lin, Raymond S. M. Wong, Wa Li, Edmond S. K. Ma, Jun Li, Gianni Panagiotou, Joycelyn P. Y. Sim, Albert K. W. Lie, Yok‐Lam Kwong
Publikováno v:
Cancer Medicine, Vol 9, Iss 10, Pp 3371-3382 (2020)
Abstract Clofarabine is active in refractory/relapsed acute myeloid leukemia (AML). In this phase 2 study, we treated 18‐ to 65‐year‐old AML patients refractory to first‐line 3 + 7 daunorubicin/cytarabine induction or relapsing after 3 + 7 in
Externí odkaz:
https://doaj.org/article/2744c5249b7a4f84a43188e34f729a01
Autor:
Vincent C.C. Cheng, Siddharth Sridhar, Shuk-Ching Wong, Sally C.Y. Wong, Jasper F.W. Chan, Cyril C.Y. Yip, Chi-Hung Chau, Timmy W.K. Au, Yu-Yan Hwang, Carol S.W. Yau, Janice Y.C. Lo, Cheuk-Kwong Lee, Kwok-Yung Yuen
Publikováno v:
Emerging Infectious Diseases, Vol 24, Iss 1, Pp 49-57 (2018)
Japanese encephalitis virus (JEV) is a mosquitoborne virus endemic to China and Southeast Asia that causes severe encephalitis in
Externí odkaz:
https://doaj.org/article/29a32d6308cb4f34a448274a577a71c5
Autor:
Wing-Shan See, Edwina Kam-fung So, Gloria Yu-Yan Hwang, Leanne Chin, Lawrence Ip, Wendy Wai-man Lam, Shau-yin Ha, Yiu-fai Cheung
Publikováno v:
International Journal of Cardiology: Heart & Vasculature, Vol 38, Iss , Pp 100947- (2022)
Background: We hypothesize that cardiac magnetic resonance (CMR) native T1 is associated with myocardial deformation in thalassaemia patients. The present study aimed to compare CMR native T1 values to conventional T2* values in patients with beta-th
Externí odkaz:
https://doaj.org/article/ce8c697c76d04fbdbe0204424a2e6265
Autor:
Thomas S. Y. Chan, Albert K. W. Lie, Joycelyn P Y Sim, Eric Tse, Yok-Lam Kwong, Garret M. K. Leung, Yu-Yan Hwang
Publikováno v:
Annals of Hematology. 101:155-163
Graft-versus-host disease (GVHD) is an important complication after allogeneic haematopoietic stem cell transplantation (HSCT). Corticosteroids are the standard first-line treatment. Steroid-resistant/-dependent (SR/D) acute and chronic GVHD (aGVHD,
Publikováno v:
Annals of Hematology. 101:1149-1152
Background:Posaconazole is superior to fluconazole/itraconazole in preventing invasive fungal diseases (IFDs) in neutropenic patients. Whether the higher cost of posaconazole is offset by decreases in IFDs in a given institute requires cost-effective
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d7e077114c013245fa8839e1ab4ec38
Autor:
Eric Tse, Yok-Lam Kwong, Thomas S. Y. Chan, Yu-Yan Hwang, Chor Sang Chim, Anskar Y.H. Leung, Pek-Lan Khong
Publikováno v:
Hematological Oncology. 38:726-736
The efficacy and safety of low-dose anti-PD1 antibodies in relapsed/refractory classical Hodgkin lymphoma (cHL) require confirmation. Pembrolizumab (100 mg every 3 weeks, Q3W) or nivolumab (40 mg Q2W) were administered to patients with relapsed/refra